Summary and Conclusion

This chapter has reviewed the evidence related to the epidemiology, natural history, and screening of four common cancers (breast, cervical, colorectal, and prostate). It presents this evidence within the context of the challenges of primary care practice and emphasizes the need to view cancer screening as a process of care. Ensuring access to screening and treatment for all is necessary to achieve the potential for mortality reduction afforded by current screening technologies. Regardless of healthcare coverage, organized systems are needed to ensure progress throughout the continuum of care. Implementation of the numerous steps and transitions in this continuum requires the interest, commitment, and collaborative action of patients, primary care providers, specialty care providers, administrators, and public health officials. Only through this collaboration can mortality reduction be maximized.171


1. Schwartz LM, Woloshin S, Fowler FJ Jr, Welch HG. Enthusiasm for cancer screening in the United States. JAMA 2004;291:71-78.

2. Prorok PC. Evaluation of screening programs for the early detection of cancer. In: Cornell RG (ed). Statistical Methods for Cancer Studies. New York: Dekker, 1984:267-328.

3. Ernster VL. Mammography screening for women aged 40 through 49: a guidelines saga and a clarion call for informed decision making. Am J Public Health 1997;87:1103-1106.

4. Baines CJ. Mammography screening: are women really giving informed consent? J Natl Cancer Inst 2003;95:1508-1511.

5. Berg AO. Mammography screening: are women really giving informed consent? (Counterpoint). J Natl Cancer Inst 2003; 95:1511-1512.

6. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd ed. Report of the U.S. Preventive Services Task Force. Baltimore: U.S. Preventive Services Task Force, 1996.

7. Humphrey LL, Helfand M, Chan BKS, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:347-360.

8. Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:132-141.

9. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002;52:342-362.

10. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin 2003;53:27-43.

11. Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:917-929.

12. Zapka JG, Taplin SH, Solberg LI, Manos MM. A framework for improving the quality of cancer care: the case of breast and cervical cancer screening. Cancer Epidemiol Biomarkers Prev 2003;12:4-13.

13. Yabroff KR, Washington KS, Leader A, Neilson E, Mandelblatt J. Is the promise of cancer-screening programs being compromised? Quality of follow-up care after abnormal screening results. Med Care Res Rev 2003;60:294-331.

14. U.S. Preventive Services Task Force (ed) Guide to Clinical Preventive Services. Baltimore: Williams & Wilkins, 1996:xxvi.

15. Weiss NS. Control definition in case-control studies of the efficacy of screening and diagnostic testing. Am J Epidemiol 1983;118:457-460.

16. Hakama M, Louhivuori K. A screening programme for cervical cancer that worked. Cancer Surv 1988;7:403-416.

17. Nystrom L, Andersson I, Bjurstam N, et al. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002;359:909-919.

18. Selby JV, Friedman GD, Quesenberry CP, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992;326:653-657.

19. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887-1892.

20. Benson K, Hartz AJ. A comparison of observational studies and randomized controlled trials. N Engl J Med 2004;342:1878-1885.

21. Tudiver F, Guibert R, Haggerty J, et al. What influences family physicians' cancer screening decisions when practice guidelines are unclear or conflicting? J Fam Pract 2002;51:760.

22. Cancer facts and figures 2004. Atlanta, GA: American Cancer Society, 2004. (Accessed February 2, 2004, at http://www.cancer. org/downloads/STT/CAFF2004PWSecured.pdf.)

23. Breast cancer facts & figures 2003-2004. Atlanta, GA: American Cancer Society, 2004. (Accessed January 21, 2004, at http:// Facts_Figures_2003-2004.asp.)

24. Probability of developing or dying of cancer: breast cancer (DEVCAN). Bethesda, MD: National Cancer Institute, SEER, 2003. (Accessed January 21, 2004, at faststats/html/dev_breast.html.)

25. SEER 12 Registries Incidence and Mortality (2002 submission). Bethesda, MD: National Cancer Institute, SEER, 2002. (Accessed January 21, 2004, at dev_breast.html.)

26. Cancer facts and figures 2003. Atlanta, GA: American Cancer Society, 2003. (Accessed December 30, 2003, at http://

27. International Agency for Research on Cancer. Breast Cancer Screening, vol 7. Lyon, France: IARC Press, 2002.

28. Duffy SW, Day NE, Tabar L, Chen HH, Smith TC. Markov models of breast tumor progression: some age-specific results. J Natl Cancer Inst Monogr 1997;22:93-97.

29. Shen Y, Zelen M. Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations. J Clin Oncol 2001;19:3490-3499.

30. Kerlikowske K, Molinaro A, Cha I, et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst 2003; 95:1692-1702.

31. Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of ductal carcinoma in situ in women undergoing screening mam-mography. J Natl Cancer Inst 2002;94:1546-1554.

32. Barton MB, Harris RH, Feltcher SW. Does this patient have breast cancer? The screening clinical breast examination: should it be done? How. JAMA 1999;282:1270-1280.

33. Hendrick RE, Chrvala CA, Plott CM, et al. Improvement in mammography quality control: 1987-1995. Radiology 1998;207: 663-668.

34. Beam CA, Layde PM, Sullivan DC. Variability in the interpretation of screening mammograms by US radiologists. Arch Intern Med 1996;156:209-213.

35. Elmore JG, Wells CK, Lee CH, Howard DH, Feinstein AR. Variability in radiologists' interpretations of mammograms. N Engl J Med 1994;331:1493-1499.

36. Taplin SH, Rutter CM, Finder C, et al. Screening mammogra-phy: clinical image quality and the risk of interval breast cancer. AJR 2002;178:797-803.

37. American College of Radiology (ACR). Breast Imaging Reporting and Data System (BI-RADSTM), 3rd ed. Reston, VA: American College of Radiology, 1998.

38. Bi-Rads®-Mammography: Assessment Categories. Reston, VA: American College of Radiology, 2003. (Accessed February 2, 2004, at mammo_assess.pdf.)

39. Kerlikowske K, Grady D, Barclay J, Sickles EA, Ernster V. Effect of age, breast density, and family history on the sensitivity of first screening mammography. JAMA 1996;276:33-38.

40. Yankaskas BC, Taplin SH, Ichikawa L, et al. Association between mammography timing and measures of screening performance in the U.S. Radiology (in press).

41. Carney PA, Miglioretti DL, Yankaskas BC, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 2003;138:168-175.

42. Pisano ED, Kuzmiak C, Koomen M, Cance W. What every surgical oncologist should know about digital mammography. Semin Surg Oncol 2001;20:181-186.

43. Lewin JM, D'Orsi CJ, Hendrick RE, et al. Clinical comparison of full-field digital mammography and film-screen mammogra-phy for detection of breast cancer. AJR Am J Roentgenol 2002; 179:671-677.

44. James JJ. The current status of digital mammography. Clin Radiol 2004;59:1-10.

45. Roque AC, Andre TC. Mammography and computerized decision systems: a review. Ann N Y Acad Sci 2002;980:83-94.

46. Gur D, Sumkin JH, Rockette HE, et al. Changes in breast cancer detection and mammography recall rates after the introduction of a computer-aided detection system. J Natl Cancer Inst 2004; 96:185-190.

47. Teaching Atlas of Breast Ultrasound, 2nd ed. New York: Thieme, 1996.

48. Kerlikowske K, Smith-Bindman R, Ljung BM, Grady D. Evaluation of abnormal mammography results and palpable breast abnormalities. Ann Intern Med 2003;139:274-284.

49. Sevilla C, Moatti JP, Julian-Reynier C, et al. Testing for BRCA1 mutations: a cost-effectiveness analysis. Eur J Hum Genet 2002; 10:599-606.

50. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRACA1 and BRCA2. JAMA 1997;27:997-1003.

51. Miller AB, To T, Baines CJ, Wall C. Canadian National Breast Screening Study 2: 13-year results of a randomized trial in women aged 50-59 years. J Natl Cancer Inst 2000;92:1490-1499.

52. Anderson BO, Braun S, Lim S, et al. Early detection of breast cancer in countries with limited resources. Breast J 2003; 9:S51-S59.

53. Thomas DB, Gao DL, Ray RM, et al. Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst 2002;94:1445-1457.

54. Duffy SW, Tabar L, Chen HH, et al. The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties. Cancer (Phila) 2002;95:458-469.

55. Olsen O, Gotzsche PC. Systematic review of screening for breast cancer with mammography. Lancet 2001;358:9290.

56. Green BB, Taplin SH. Breast cancer screening controversies. J Am Board Fam Pract 2003;16:233-241.

57. Breast Cancer Screening Among Women in Their Forties: An Overview of the Issues. Bethesda MD: National Institutes of Health, 1997.

58. Breast Screening Frequency Trial Group. The frequency of breast cancer screening: results from the UKCCCR Randomised Trial. Eur J Cancer 2002;38:1458-1464.

59. Smith RA, Saslow D, Sawyer KA, et al. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin 2003;53:141-169.

60. World Health Organization and International Agency for Research on Cancer. World Cancer Report. Lyon, France: International Agency for Research on Cancer, 2003.

61. Taylor VM, Jackson JC, Schwartz SM, Tu SP, Thompson B. Cervical cancer among Asian American women: a neglected public health problem? Asian Am Pac Isl J Health 1996;4:327-342.

62. Franco EL. Primary screening of cervical cancer with human papillomavirus tests. J Natl Cancer Inst Monogr 2003;31:89-96.

63. IARC Working Group on Evaluation of Cervical Cancer Screening Programmes. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. Br Med J 1986;293:659-664.

64. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. Can Med Assoc J 2001;164:1017-1025.

65. Levine PB. Parental involvement laws and fertility behavior. J Health Econ 2003;22:861-878.

66. McCann MF, Irwin DE, Walton LA, et al. Nicotine and cotinine in the cervical mucus of smokers, passive smokers, and non-smokers. Cancer Epidemiol Biomarkers Prev 1992;1:125-129.

67. Coker AL, Bond SM, Williams A, Gerasimova T, Pirisi L. Active and passive smoking, high-risk human papillomaviruses and cervical neoplasia. Cancer Detect Prev 2002;26:121-128.

68. Brinton LA, Hamman RF, Huggins GR, et al. Sexual and reproductive risk factors for invasive squamous cell cervical cancer. J Natl Cancer Inst 1987;79:23-30.

69. Ferenczy A, Coutlee F, Franco E, Hankins C. Human papillo-mavirus and HIV coinfection and the risk of neoplasias of the lower genital tract: a review of recent developments. Can Med Assoc J 2003;169:431-424.

70. Sierra-Torres CH, Au WW, Arrastia CD, et al. Polymorphisms for chemical metabolizing genes and risk for cervical neoplasia. Environ Mol Mutagen 2003;41:69-76.

71. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000; 132:810-819.

72. Davey DD. Cervical cytology classification and the Bethesda System. Cancer J 2003;9:327-334.

73. Sasieni P, Cuzick J. Could HPV testing become the sole primary cervical screening test? J Med Screen 2002;9:49-51.

74. Sherman ME. Future directions in cervical pathology. J Natl Cancer Inst Monogr 2003;31:72-79.

75. Ronco G, Vineis C, Montanari G, et al. Impact of the AutoPap (currently Focalpoint) primary screening system location guide use on interpretation time and diagnosis. Cancer (Phila) 2003; 99:83-88.

76. Hartmann KE, Nanda K, Hall S, Myers E. Technologic advances for evaluation of cervical cytology: is newer better? Obstet Gynecol Surv 2001;56:765-774.

77. Wright TC Jr. Cervical cancer screening using visualization techniques. J Natl Cancer Inst Monogr 2003;31:66-71.

78. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003;95:46-52.

79. Sawaya GF, McConnell KJ, Kulasingam SL, et al. Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med 2003;349:1501-1509.

80. Sasieni P, Adams J, Cuzick J. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer 2003;89:88-93.

81. Cervical cancer—screening. Rockville, MD: U.S. Preventive Services Task Force, 2003. (Accessed January 14, 2004, at]

82. U.S. Preventive Services Task Force. Screening for cervical cancer. In: DiGuiseppi C, Atkins D, Woolf S (eds). Guide to Clinical Preventive Services: Report of the US Preventive Services Task Force. Baltimore: Williams & Wilkins, 1996:105-117.

83. Pasche B, Mulcahy M, Benson AB III. Molecular markers in prognosis of colorectal cancer and prediction of response to treatment. Best Pract Res Clin Gastroenterol 2002;16:331-345.

84. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-170.

85. Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med 2003;138:560-570.

86. Hofstad B, Vatn M. Growth rate of colon polyps and cancer. Gastrointest Endosc Clin N Am 1997;7:345-363.

87. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319:525-532.

88. Ahlquist DA, Shuber AP. Stool screening for colorectal cancer: evolution from occult blood to molecular markers. Clin Chim Acta 2002;315:157-168.

89. Levin B, Brooks D, Smith RA, Stone A. Emerging technologies in screening for colorectal cancer: CT colonography, immuno-chemical fecal occult blood tests, and stool screening using molecular markers. CA Cancer J Clin 2003;53:44-55.

90. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale— update based on new evidence. Gastroenterology 2003;124: 544-560.

91. Chen CD, Yen MF, Wang WM, Wong JM, Chen TH. A case-cohort study for the disease natural history of adenoma-carcinoma and de novo carcinoma and surveillance of colon and rectum after polypectomy: implication for efficacy of colonoscopy. Br J Cancer 2003;88:1866-1873.

92. Anderson WF, Guyton KZ, Hiatt RA, et al. Colorectal cancer screening for persons at average risk. J Natl Cancer Inst 2002; 94:1126-1133.

93. Herrinton LJ, Selby JV, Friedman GD, Quesenberry CP, Weiss NS. Case-control study of digital-rectal screening in relation to mortality from cancer of the distal rectum. Am J Epidemiol 1995;142:961-964.

94. Young GP, St John DJ, Winawer SJ, Rozen P. Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies: a WHO (World Health Organization) and OMED (World Organization for Digestive Endoscopy) report. Am J Gastroen-terol 2002;97:2499-2507.

95. Allison JE, Tekawa IS, Ransom LJ, Adrian AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996;334:155-159.

96. van Ballegooijen M, Habbema JDF, Boer R, Zauber AG, Brown ML. Report to the Agency for Healthcare Research and Quality. A comparison of the cost-effectiveness of fecal occult blood tests with different test characteristics in the context of annual screening in the Medicare population. Baltimore, MD: Centers for Medicare and Medicaid Services, 2003.

97. Cole SR, Young GP, Esterman A, Cadd B, Morcom J. A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. J Med Screen 2003;10:117-122.

98. Pignone M, Campbell MK, Carr C, Phillips C. Meta-analysis of dietary restriction during fecal occult blood testing. Eff Clin Pract 2001;4:150-156.

99. Ahlquist DA, Wieand HS, Moertel CG, et al. Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA 1993; 269:1262-1267.

100. Ransohoff DF, Lang CA. Improving the fecal occult-blood test. N Engl J Med 1996;334:189-190.

101. Levin B, Hess K, Johnson C. Screening for colorectal cancer. A comparison of 3 fecal occult blood tests. Arch Intern Med 1997;157:970-976.

102. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993;328:1365-1371.

103. Ransohoff DF, Lang CA. Part I: Suggested technique for fecal occult blood testing and interpretation in colorectal cancer screening. Ann Intern Med 1997;126:808-810.

104. Vernon S. Adherence to colorectal cancer screening. Ann NY Acad Sci 1995;768:292-295.

105. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-1477.

106. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-1471.

107. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000;343:1603-1607.

108. Robinson MH, Pye G, Thomas WM, Hardcastle JD, Mangham CM. Haemoccult screening for colorectal cancer: the effect of dietary restriction on compliance. Eur J Surg Oncol 1994; 20:545-548.

109. Cole SR, Young GP. Effect of dietary restriction on participation in faecal occult blood test screening for colorectal cancer. Med J Aust 2001;175:195-198.

110. Ko CW, Dominitz JA, Nguyen TD. Fecal occult blood testing in a general medical clinic: comparison between guaiac-based and immunochemical-based tests. Am J Med 2003;115:111-114.

111. Walsh JM, Terdiman JP. Colorectal cancer screening: scientific review. JAMA 2003;289:1288-1296.

112. Rex DK, Johnson DA, Lieberman DA, Burt RW, Sonnenberg A. Colorectal cancer prevention 2000: screening recommendations of the American College of Gastroenterology. Am J Gastroen-terol 2000;95:868-877.

113. Eloubeidi MA, Wallace MB, Desmond R, Farraye FA. Female gender and other factors predictive of a limited screening flexible sigmoidoscopy examination for colorectal cancer. Am J Gas-troenterol 2003;98:1634-1639.

114. Pickhardt PJ, Choi JR, Hwang I, et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 2003;349:2191-2200.

115. Rex DK, Rahmani EY, Haseman JH, et al. Relative sensitivity of colonoscopy and barium enema for detection of colorectal cancer in clinical practice. Gastroenterology 1997;112:17-23.

116. Rex DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 1997;112:24-28.

117. Gatto NM, Frucht H, Sundararajan V, et al. Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J Natl Cancer Inst 2003;95:230-236.

118. Schoen RE, Weissfeld JL, Bowen NJ, Switzer G, Baum A. Patient satisfaction with screening flexible sigmoidoscopy. Arch Intern Med 2000;160:1790-1796.

119. Lurie JD, Welch HG. Diagnostic testing following fecal occult blood screening in the elderly. J Natl Cancer Inst 1999;91: 1641-1646.

120. Turner B, Myers ME, Hyslop T, et al. Physician and patient factors associated with ordering a colon evaluation after a positive fecal occult blood test. J Gen Intern Med 2003;18:357-363.

121. Sussman GL, Beezhold DH. Latex allergy—a clinical perspective. J Long Term Eff Med Implants 1994;4:95-101.

122. Misselbeck WJ, Gray KR, Uphold RE. Latex induced anaphy-laxis: a case report. Am J Emerg Med 1994;12:445-447.

123. Ownby DR, Tomlanovich M, Sammons N, McCullough J. Ana-phylaxis associated with latex allergy during barium enema examinations. AJR Am J Roentgenol 1991;156:903-908.

124. Johnson CD, Ahlquist DA. Computed tomography colonogra-phy (virtual colonoscopy): a new method for colorectal screening. Gut 1999;44:301-305.

125. Dong SM, Traverso G, Johnson C, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001;93:858-865.

126. Traverso G, Shuber A, Olsson L, et al. Detection of proximal colorectal cancers through analysis of faecal DNA. Lancet 2002;359:403-404.

127. Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000;119: 1219-1227.

128. Walsh JM, Terdiman JP. Colorectal cancer screening: clinical applications. JAMA 2003;289:1297-1302.

129. Helm J, Choi J, Sutphen R, et al. Current and evolving strategies for colorectal cancer screening. Cancer Control 2003;10: 193-204.

130. Hardcastle JD, Armitage NC, Chamberlain J, et al. Fecal occult blood screening for colorectal cancer in the general population. Cancer (Phila) 1986;58:397-403.

131. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999;91:434-437.

132. Saito H, Soma Y, Koeda J, et al. Reduction in risk of mortality from colorectal cancer by fecal occult blood screening with immunochemical hemagglutination test. A case-control study. Int J Cancer 1995;61:465-469.

133. Newcomb PA, Storer BE, Morimoto LM, Templeton A, Potter JD. Long-term efficacy of sigmoidoscopy in the reduction of colorectal cancer incidence. J Natl Cancer Inst 2003;95:622-625.

134. Winawer SJ, Flehinger BJ, Schottenfeld D, Miller DG. Screening for colorectal cancer with fecal occult blood testing and sigmoi-doscopy. J Natl Cancer Inst 1993;85:1311-1318.

135. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Controlled Clin Trials 2000;21:273S-309S.

136. Atkin WS, Hart A, Edwards R, et al. Uptake, yield of neoplasia, and adverse effects of flexible sigmoidoscopy screening. Gut 1998;42:560-565.

137. Gondal G, Grotmol T, Hofstad B, et al. The Norwegian Colo-rectal Cancer Prevention (NORCCAP) screening study: baseline findings and implementations for clinical work-up in age groups 50-64 years. Scand J Gastroenterol 2003;38:635-642.

138. Muller AD, Sonnenberg A. Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans. Ann Intern Med 1995;123:904-910.

139. Kavanagh AM, Giovannucci EL, Fuchs CS, Colditz GA. Screening endoscopy and risk of colorectal cancer in United States men. Cancer Causes Control 1998;9:455-462.

140. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med 1993; 329:1977-1981.

141. Muller AD, Sonnenberg A. Protection by endoscopy against death from colorectal cancer. A case-control study among veterans. Arch Intern Med 1995;155:1741-1748.

142. Ransohoff DF, McNaughton CM, Fowler FJ. Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedback. Am J Med 2002;113: 663-667.

143. Hoffman RM, Hunt WC, Gilliland FD, Stephenson RA, Potosky AL. Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study. Cancer (Phila) 2003;97:1653-1662.

144. Potosky AL, Reeve BB, Clegg LX, et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 2002; 94:430-437.

145. Cookson MS. Prostate cancer: screening and early detection. Cancer Control 2004;8:133-140.

146. Potosky AL, Feuer EJ, Levin DL. Impact of screening on incidence and mortality of prostate cancer in the United States. Epidemiol Rev 2001;23:181-186.

147. Perron L, Moore L, Bairati I, Bernard PM, Meyer F. PSA screening and prostate cancer mortality. C Med Assoc J 2002; 166:586-591.

148. Tornblom M, Eriksson H, Franzen S, et al. Lead time associated with screening for prostate cancer. Int J Cancer 2004;108: 122-129.

149. Partin AW, Brawer MK, Bartsch G, et al. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol 2003; 170:1787-1791.

150. Caplan A, Kratz A. Prostate-specific antigen and the early diagnosis of prostate cancer. Am J Clin Pathol 2002;117:S104-S108.

151. Labrie F, Candas B, Dupont A, et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999;38:83-91.

152. Potosky AL, Legler J, Albertsen PC, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000;92:1582-1592.

153. Schmid HP, Prikler L, Semjonow A. Problems with prostate-specific antigen screening: a critical review. Recent Results Cancer Res 2003;163:226-231.

154. McCarthy BD, Ulcickas-Yood M, Boohaker EA, et al. Inadequate follow-up of abnormal mammograms. Am J Prev Med 1996; 12:282-288.

155. Sung HY, Kearney KA, Miller M, et al. Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan. Cancer (Phila) 2000;88:2283-2289.

156. Hiatt RA, Pasick RJ, Stewart S, et al. Community-based cancer screening for underserved women: design and baseline findings from the Breast and Cervical Cancer Intervention Study. Prev Med 2001;33:190-203.

157. Hiatt RA, Klabunde C, Breen N, Swan J, Ballard-Barbash R. Cancer screening practices from National Health Interview Surveys: past, present, and future. J Natl Cancer Inst 2002;94: 1837-1846.

158. Swan J, Breen N, Coates RJ, Rimer BK, Lee NC. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer (Phila) 2003;97:1528-1540.

159. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA 2003;289:1414-1420.

160. Klabunde CN, Frame PS, Meadow A, et al. A national survey of primary care physicians' colorectal cancer screening recommendations and practices. Prev Med 2003;36:352-362.

161. Lawson HW, Henson R, Bobo JK, Kaeser MK. Implementing recommendations for the early detection of breast and cervical cancer among low-income women. MMWR Morbid Mortal Wkly Rep 2000;49(RR02):35-55.

162. Mandelblatt JS, Yabroff KR, Kerner JF. Equitable access to cancer services: a review of barriers to quality care. Cancer (Phila) 1999; 86:2378-2390.

163. Hidden costs, value lost: uninsurance in America. Washington, DC: Institute of Medicine, 2003. (Accessed February 2, 2004, at

164. Breen N, Wagener DK, Brown ML, Davis WW, Ballard-Barbash R. Progress in cancer screening over a decade: results of cancer screening from the 1987, 1991, and 1998 National Health Interview Surveys. J Natl Cancer Inst 2001;93:1704-1713.

165. Cokkinides V, Chao A, Smith RA, Vernon SW, Thun MJ. Correlates of underutilization of colorectal cancer screening among U.S. adults, age 50 years and older. Prev Med 2003;36: 85-91.

166. Cooper GS, Koroukian SM. Racial disparities in the use of and indications for colorectal procedures in Medicare beneficiaries. Cancer (Phila) 2004;100:418-424.

167. Singh GK, Miller BA, Hankey BF, Feuer EJ, Pickle LW. Changing area socioeconomic patterns in U.S. cancer mortality, 1950-1998: Part I. All cancers among men. J Natl Cancer Inst 2002;94:904-915.

168. Sambamoorthi U, McAlpine DD. Racial, ethnic, socioeconomic, and access disparities in the use of preventive services among women. Prev Med 2003;37:475-484.

169. Jackson JC, Taylor VM, Chitnarong K, et al. Development of a cervical cancer control intervention program for Cambodian American women. J Community Health 2000;25:359-375.

170. Tu SP, Taplin SH, Barlow WE, Boyko EJ. Breast cancer screening by Asian-American women in a managed care environment. Am J Prev Med 1999;17:55-61.

171. Zapka JG. Interventions for patients, providers, and health care organizations. Cancer 2004;101(suppl 5):1165-1187.

172. Stone EG, Morton SC, Hulscher ME, et al. Interventions that increase use of adult immunization and cancer screening services: a meta-analysis. Ann Intern Med 2002;136:641-651.

173. Stockwell DH, Woo P, Jacobson BC, et al. Determinants of colo-rectal cancer screening in women undergoing mammography. Am J Gastroenterol 2003;98:1875-1880.

174. Yarnall KS, Pollak KI, Ostbye T, Krause KM, Michener JL. Primary care: is there enough time for prevention? Am J Public Health 2003;93:635-641.

175. Yabroff KR, Mandelblatt JS. Interventions targeted toward patients to increase mammography use. Cancer Epidemiol Bio-markers Prev 1999;8:749-757.

176. Mandelblatt JS, Yabroff KR. Effectiveness of interventions designed to increase mammography use: a meta-analysis of provider-targeted strategies. Cancer Epidemiol Biomarkers Prev 1999;8:759-767.

177. Wagner TH. The effectiveness of mailed patient reminders on mammography screening: a meta-analysis. Am J Prev Med 1998; 14:64-70.

178. Yabroff KR, Kerner JF, Mandelblatt JS. Effectiveness of interventions to improve follow-up after abnormal cervical cancer screening. Prev Med 2000;31:429-439.

179. Mandelblatt J, Kanetsky PA. Effectiveness of interventions to enhance physician screening for breast cancer. J Fam Pract 1995; 40:162-171.

180. Lam TK, McPhee SJ, Mock J, et al. Encouraging Vietnamese-American women to obtain Pap tests through lay health worker outreach and media education. J Gen Intern Med 2003; 18:516-524.

181. Glasgow RE, Orleans CT, Wagner EH. Does the chronic care model serve also as a template for improving prevention? Milbank Q 2001;79:579-612.

182. Dietrich AJ, Carney PA, Winchell CW, Sox CH, Reed SC. An office systems approach to cancer prevention in primary care. Cancer Pract 1997;5:375-381.

183. Carney-Gersten P, Keller A, Landgraf J, Dietrich AJ. Tools, teamwork, and tenacity: an office system for cancer prevention. J Fam Pract 1992;35:388-394.

184. Taplin SH, Galvin MS, Payne T, Coole D, Wagner E. Putting population-based care into practice: real option or rhetoric? J Am Board Fam Pract 1998;11:116-126.

185. Myers RE, Turner B, Weinberg D, et al. Complete diagnostic evaluation in colorectal cancer screening: research design and baseline findings. Prev Med 2001;33:249-260.

186. Burack RC, Simon MS, Stano M, George J, Coombs J. Follow-up among women with an abnormal mammogram in an HMO: is it complete, timely, and efficient? Am J Manag Care 2000; 6:1102-1113.

187. Paskett E, Rimer B. Psychosocial effects of abnormal pap tests and mammograms: a review. J Womens Health 1995;4:73-82.

188. Institute of Medicine, Commission on Life Sciences National Research Council. Ensuring Quality Cancer Care. Washington, DC: National Academy Press, 1999.

189. Institute of Medicine. Unequal Treatment: Confronting Racial and Ethnic Disparities in Healthcare. Washington, DC: National Academies Press, 2003.

190. Townsley CA, Naidoo K, Pond GR, et al. Are older cancer patients being referred to oncologists? A mail questionnaire of Ontario primary care practitioners to evaluate their referral patterns. J Clin Oncol 2003;21:4627-4635.

191. Earle CC, Neumann PJ, Gelber RD, Weinstein MC, Weeks JC. Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol 2002;20:1786-1792.

192. Freeman HP, Muth BJ, Kerner JF. Expanding access to cancer screening and clinical follow-up among the medically under-served. Cancer Pract 1995;3:19-30.

193. Lantz PM, Weisman CS, Itani Z. A disease-specific Medicaid expansion for women. The Breast and Cervical Cancer Prevention and Treatment Act of 2000. Womens Health Issues 2003; 13:79-92.

194. Bobo J, Lee N. Factors associated with accurate cancer detection during a clinical breast examination. Ann Epidemiol 2000; 10:463.

195. Oestreicher N, White E, Lehman CD, et al. Predictors of sensitivity of clinical breast examination (CBE). Breast Cancer Res Treat 2002;76:73-81.

196. Shapiro S, Benet W, Strax P, Venet L. Periodic Screening for Breast Cancer: The Health Insurance Plan Project and Its Sequelae, 1963-1986. Baltimore: Johns Hopkins University Press, 1988:55.

197. Miller AB, To T, Baines CJ, Wall C. The Canadian National Breast Screening Study. 1: Breast cancer mortality after 11 to 16 years of follow-up. Ann Intern Med 2002;137:E305-E315.

198. Alexander FE, Anderson TJ, Brown HK, et al. 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening. Lancet 1999;353:1903-1908.

199. Bjurstam N, Bjorneld L, Duffy SW, et al. The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39-49 years at randomization. Cancer (Phila) 1997;80:2091-2099.

200. Frisell J, Lidbrink E, Hellstrom L, Rutqvist LE. Follow-up after 11 years: update of mortality results in the Stockholm mam-mographic screening trial. Breast Cancer Res Treat 1997; 45:263-270.

201. Andersson I, Aspegren K, Janzon L, et al. Mammographic screening and mortality from breast cancer: the Malmo mammo-graphic screening trial. Br Med J 1988;297:943-948.

202. Tabar L, Vitak B, Chen HH, et al. The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. Radiol Clin N Am 2000;38:625-651.

203. Wright TC Jr, Cox JT, Massd LS, Twiggs LB, Wilkinson EJ. 2001 Consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 2002;278:2120-2129.

204. Nygard JF, Skare GB, Thoresen SO. The cervical cancer screening programme in Norway, 1992-2000: changes in Pap smear coverage and incidence of cervical cancer. J Med Screen 2002; 9:86-91.

205. Wright TC, Cox JT, Massad LS, et al. 2001 consensus guidelines for the management of women with cervical intraepithelial neo-plasia. J Lower Genital Tract Dis 2003;7:154-167.

206. Manos M, Kinney WK, Hurley LB, et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999;281:1605-1610.

207. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions: standardizing data on outcomes [see comments]. N Engl J Med 1998;339:380-386.

208. Day NE. Effect of cervical cancer screening in Scandinavia. Obstet Gynecol 1984;63:714-718.

209. Lynge E. Effect of organized screening on incidence and mortality of cervical cancer in Denmark. Cancer Res 1989;49: 2157-2160.

210. Bigaard J. Cervical cancer screening in Denmark. Eur J Cancer 2000;36:2198-2204.

211. Greenberg PD, Bertario L, Gnauck R, et al. A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy. Am J Gastroenterol 2000;95: 1331-1338.

212. Lieberman DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 2001;345:555-560.

213. van den Akker-van Marle ME, van Ballegooijen M, van Oortmarssen GJ, Boer R, Habbema JD. Cost-effectiveness of cervical cancer screening: comparison of screening policies. J Natl Cancer Inst 2002;94:193-204.

214. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997;112:594-642.

215. Wherry DC, Thomas WM. The yield of flexible fiberoptic sig-moidoscopy in the detection of asymptomatic colorectal neo-plasia. Surg Endosc 1994;8:393-395.

216. Rex DK. Current colorectal cancer screening strategies: overview and obstacles to implementation. Rev Gastroenterol Disord 2002;2:S2-S11.

217. Tagore KS, Lawson MJ, Yucaitis JA. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer 2004; 3:47-53.

218. Mulhall BP. Recent findings on test performance. Washington, DC: Walter Reed Army Medical Center, 2003 (unpublished work).

219. U.S. Preventive Services Task Force. Screening for prostate cancer: recommendations and rationale. Am Fam Physician 2003;67:787-792.

220. Friedman GD, Hiatt RA, Quesenberry CP Jr, Selby JV. Case-control study of screening for prostatic cancer by digital rectal examinations. Lancet 1991;337:1526-1529.

221. Jacobsen SJ, Bergstralh EJ, Katusic SK, et al. Screening digital rectal examination and prostate cancer mortality: a population-based case-control study. Urology 1998;52:173-179.

222. Richert-Boe KE, Humphrey LL, Glass AG, Weiss NS. Screening digital rectal examination and prostate cancer mortality: a case-control study. J Med Screen 1998;5:99-103.

223. Lu-Yao G, Albertsen PC, Stanford JL, et al. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 2002;325:740.

224. Bartsch G, Horninger W, Klocker H, et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001;58:417-424.

Squash Smoking

Squash Smoking

Squash Smoking Hypnotherapy For Breaking Bad Habits With Smoking Series Presenting your hypnotherapy series for success, enlightenment and breaking bad habits with smoking.

Get My Free Ebook


  • hiwet
    What is tu tenacity radiation therapy?
    2 years ago

Post a comment